571 related articles for article (PubMed ID: 36741400)
1. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy.
Yang K; Zhao Y; Sun G; Zhang X; Cao J; Shao M; Liang X; Wang L
Front Immunol; 2022; 13():1081546. PubMed ID: 36741400
[TBL] [Abstract][Full Text] [Related]
2. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
3. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
4. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
5. Breaking down barriers: The potential of smarter CAR-engineered NK cells against solid tumors.
Khawar MB; Gao G; Rafiq M; Shehzadi A; Afzal A; Abbasi MH; Sheikh N; Afzal N; Ashraf MA; Hamid SE; Shahzaman S; Kawish N; Sun H
J Cell Biochem; 2023 Aug; 124(8):1082-1104. PubMed ID: 37566723
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
7. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
8. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
[TBL] [Abstract][Full Text] [Related]
9. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
10. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
[TBL] [Abstract][Full Text] [Related]
12. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
Zhuang X; Long EO
Front Immunol; 2022; 13():840844. PubMed ID: 35585985
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK cells for cancer immunotherapy: recent advances and future directions.
Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
[TBL] [Abstract][Full Text] [Related]
14. The prospect of genetically engineering natural killer cells for cancer immunotherapy.
Poon AYC; Sugimura R
Biol Open; 2022 Dec; 11(12):. PubMed ID: 36445164
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
Peng XR; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
[TBL] [Abstract][Full Text] [Related]
16. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
18. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
19. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
20. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
